Q2 2025 Mendus AB (publ) Earnings Call Transcript
Key Points
- Mendus AB (OSTO:IMMU) presented promising data from the ADVANCE II phase 2 trial in acute myeloid leukemia (AML), showing broad immune stimulation and effectiveness across different AML subtypes.
- The company is progressing with Nortek Biologics in a manufacturing alliance to deliver large-scale GMP batches, supporting clinical development and future commercialization.
- Mendus AB (OSTO:IMMU) has strengthened its late-stage development capabilities by appointing Tariq Mughal, enhancing their strategy in hemato-oncology.
- The company received a key patent from the United States Patent and Trademark Office for the use of CADENCE cell in ovarian cancer, expanding its intellectual property portfolio.
- The CADENCE trial is gaining momentum with ongoing patient recruitment, indicating positive progress in their clinical trials.
- The cash position at the end of Q2 was SEK58.9 million, which may raise concerns about the company's financial sustainability without additional funding.
- There are still prepaid expenses related to the tech transfer, indicating ongoing financial commitments that could impact cash flow.
- The company faces a competitive clinical development landscape in AML, requiring a high number of clinical sites to recruit enough patients for trials.
- The ovarian cancer trial is still in an early phase, and the company is cautious about expressing expectations due to the need for more data.
- The registration trial for AML requires careful alignment with regulatory agencies and potential partnerships with pharmaceutical companies, which could delay progress.
Welcome to Mendus Q2 report 2025 presentation. (Operator Instructions) Now I will hand the conference over to the speakers, CEO, Eric Manting and CFO, Lotta Ferm. Please go ahead.
()-
Thank you and welcome everybody to the Q2 webcast and business update of Mendus. As a summary of the key events in Q2, we have presented data at multiple conferences of the ongoing ADVANCE II phase 2 trial in acute myeloid leukemia, showing that our immunotherapy CADENCE cell improves T cell repertoire, and also that X across a broader mutation ranges of AML. We had shown this in the past already in our earlier studies, but now also in the ADVANCE II trial, we specifically focused on a common mutation called NPM1.
The relevance of this is that we are showing and continue to show that we stimulate broad immunity against residual disease, and also that our product acts across different subtypes of AML, And that makes it very different from targeted therapies that by definition are always
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
